Date: 2014-10-21
Type of information: Treatment of the first patient
phase: 1
Announcement: treatment of the first patient
Company: Athera Biotechnologies (Sweden)
Product: antibody program PC-mAb
Action
mechanism: Athera’s fully human monoclonal antibody PC-mAb is intended for the treatment of patients with cardiovascular disease, who are at an increased risk of secondary events and death. It is known from previous published studies that low plasma levels of endogenous antibodies against phosphorylcholine (anti-PC) are linked to poor prognosis in acute heart attack patients, as well as in patients with peripheral arterial disease undergoing vein graft surgery.
Disease: cardiovascular diseases
Therapeutic area: Cardiovascular diseases
Country: Sweden
Trial details:
Latest
news: * On October 21, 2014, Athera Biotechnologies AB, a Karolinska Development AB portfolio company, announced that first dosing of healthy volunteers has been done in a Phase I study of its fully human antibody PC-mAb. This lead product candidate targets the
inflammatory component of cardiovascular disease, where current therapies are considered to be inadequate. The current Phase I study will include up to 48 healthy volunteers in a single ascending dose protocol with safety outcome measures and is performed in Uppsala by CTC Clinical Trial Consultants AB. The development costs for Athera’s lead product candidate are co-financed by the EU FP7 program, within the project CARDIMMUN.
